Skip to main content
HIGH TECH PHARM CO.,LTD. logo

HIGH TECH PHARM CO.,LTD. — Investor Relations & Filings

Ticker · 106190 ISIN · KR7106190002 KO Manufacturing
Open in API
Filings indexed 169 across all filing types
Latest filing 2019-03-14 Management Reports
Country KR South Korea
Listing KO 106190

About HIGH TECH PHARM CO.,LTD.

http://www.htpharm.com/eng/

HIGH TECH PHARM CO.,LTD. is a pharmaceutical company specializing in the development and manufacturing of active pharmaceutical ingredients (APIs), with a primary focus on sterile, carbapenem-based antibiotic raw materials. Established in 1998, the company has gained global recognition for its advanced technology and high-quality products, which are supplied to over 40 countries. A significant majority of its sales are generated from exports to demanding overseas markets, including Europe. The company operates state-of-the-art manufacturing facilities, such as its Chungju plant, designed to meet the rigorous standards of advanced regulatory authorities like the U.S. FDA and European EDQM. Through a commitment to a quality-first policy and continuous research and development, HIGH TECH PHARM aims to solidify its position as a leading global supplier of antibiotic drug substances.

Recent filings

Filing Released Lang Actions
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 95% confidence The document is a regulatory filing from a Korean company (Hitech Pharm) announcing a significant change (over 15%) in its financial structure (revenue, operating profit, net income) compared to the previous fiscal year. This is a standard regulatory disclosure required by the Korea Exchange (KRX) when financial results deviate significantly from prior periods. It is not a full annual report, but rather a specific financial disclosure announcement, which falls under the 'Regulatory Filings' category.
2019-03-14 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for the 21st Annual General Meeting of HT Pharm. It contains the meeting agenda, details on board member elections, proposed amendments to the articles of incorporation, and remuneration limits for directors and auditors. This document is a standard proxy statement/information circular provided to shareholders to solicit their participation and votes for the upcoming meeting. In the context of the provided filing categories, this fits the definition of a Proxy Solicitation & Information Statement.
2019-03-14 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from a company (Hitech Pharm) regarding the decision to pay a cash dividend. It specifies the dividend amount per share, the total dividend amount, the record date, and the board approval date. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2019-02-01 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details the resignation of an outside director at Hitech Pharm. This falls under the category of board and management changes.
2019-02-01 Korean
기타경영사항(자율공시)(충주공장 BGMP 실시상황 평가신청에 따른 식품의약품안전처 평가 적합판정)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding a regulatory approval (BGMP certification) from the Ministry of Food and Drug Safety for the company's Chungju plant. It does not fit into specific categories like financial reports, dividends, or M&A. As it is a general regulatory announcement regarding company operations, it falls under the fallback category of Regulatory Filings (RNS).
2019-01-18 Korean
[기재정정]분기보고서 (2017.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'High Tech Pharm' (주식회사 하이텍팜) for the period ending 2017.03.31. It contains detailed financial information, business descriptions, management discussions, and capital structure data. Although it mentions a 'correction' (정정신고) at the beginning, the document itself is a comprehensive interim financial report, not merely an announcement or a certification. Therefore, it is classified as an Interim/Quarterly Report. Q1 2017
2019-01-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.